ASCO 2022 | KRYSTAL-1: next steps in the field of KRASG12C-mutant cancers
Melissa Johnson, MD, Sarah Cannon Research Institute, Nashville, TN, reflects on the results from KRYSTAL-1 (NCT03785249), a Phase II study which evaluated adagrasib in patients with KRASG12C-mutant lung cancer. KRYSTAL-1 reported a response rate of 43%, a progression-free survival (PFS) of 6 months, and an overall survival (OS) of a year. Dr Johnson discusses outcomes compared to sotorasib, the only FDA approved KRASG12C inhibitor, as well as the next steps in the field of KRAS-mutant tumors. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
Transcript (edited for clarity)
We’ve heard the confirmatory results of KRYSTAL-1, it’s a trial evaluating a direct KRAS-G12C inhibitor adagrasib. The authors reported a response rate of 43%, and a PFS of six months and an overall survival of about a year. So, very similar to the sotorasib CodeBreaK100 data that was reported a couple years ago. So sotorasib has an FDA approval, we anticipate adagrasib will also gain an approval based on this data...
We’ve heard the confirmatory results of KRYSTAL-1, it’s a trial evaluating a direct KRAS-G12C inhibitor adagrasib. The authors reported a response rate of 43%, and a PFS of six months and an overall survival of about a year. So, very similar to the sotorasib CodeBreaK100 data that was reported a couple years ago. So sotorasib has an FDA approval, we anticipate adagrasib will also gain an approval based on this data. And so, at this meeting, we’re talking about what are the next steps beyond monotherapy KRAS inhibitors, both in and lung cancer patients with KRAS-G12C mutations, as well as other tumor types, colorectal, pancreatic cancer. So, there’s a lot to be excited about at ASCO 2022.
Read more...
